Design Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 28, 2026
DSGN$10.65-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(17,636) | $(17,715) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation | 157 | 159 |
| Stock-based compensation | 3,924 | 3,539 |
| Amortization of premiums on investment securities, net | (147) | (1,060) |
| Non-cash lease expense | 69 | (4) |
| Change in operating assets and liabilities: | ||
| Prepaid expense and other assets | (287) | (1,407) |
| Accounts payable and other liabilities | (2,511) | (301) |
| Net cash used in operating activities | (16,431) | (16,789) |
| Cash flows from investing activities | ||
| Purchases of investment securities | (52,589) | (86,548) |
| Proceeds from maturities of investment securities | 45,000 | 94,490 |
| Purchases of property and equipment | — | (72) |
| Net cash (used in) provided by investing activities | (7,589) | 7,870 |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 19,907 | — |
| Proceeds from the exercise of stock options | 27 | 23 |
| Net cash provided by financing activities | 19,934 | 23 |
| Net decrease in cash and cash equivalents | (4,086) | (8,896) |
| Cash and cash equivalents at beginning of period | 16,856 | 22,563 |
| Cash and cash equivalents at end of period | $12,770 | $13,667 |
| Supplemental disclosures | ||
| Increase in right-of-use-asset and operating lease liability related to lease amendment | $1,295 | $— |
| Purchases of property and equipment included in accounts payable and accrued expenses | $— | $54 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.